LSDIF (Lucy Scientific Discovery) Retained Earnings: $-49.03 Mil (As of Dec. 2023)


What is Lucy Scientific Discovery Retained Earnings?

Lucy Scientific Discovery LSDIF Retained Earnings is $-49.03 Mil as of Dec. 2023.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lucy Scientific Discovery's retained earnings for the quarter that ended in Dec. 2023 was $-49.03 Mil.

Lucy Scientific Discovery's quarterly retained earnings declined from Jun. 2023 ($-44.42 Mil) to Sep. 2023 ($-46.41 Mil) and declined from Sep. 2023 ($-46.41 Mil) to Dec. 2023 ($-49.03 Mil).

Lucy Scientific Discovery's annual retained earnings declined from Jun. 2021 ($-29.57 Mil) to Jun. 2022 ($-35.43 Mil) and declined from Jun. 2022 ($-35.43 Mil) to Jun. 2023 ($-44.42 Mil).

Lucy Scientific Discovery  (OTCPK:LSDIF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Lucy Scientific Discovery Retained Earnings Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery Retained Earnings Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Retained Earnings
-29.57 -35.43 -44.42

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -37.73 -41.84 -44.42 -46.41 -49.03

Lucy Scientific Discovery Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-49.03 Mil mean?
Lucy Scientific Discovery (LSDIF) has a Retained Earnings of $-49.03 Mil as of Dec. 2023. Retained earnings is the amount of net income not issued to shareholders. View historical data on Lucy Scientific Discovery and its competitors.
Is Lucy Scientific Discovery's Retained Earnings too high?
Lucy Scientific Discovery's current Retained Earnings is $-49.03 Mil.
How does Lucy Scientific Discovery's Retained Earnings compare to INQD and ZTS?
Lucy Scientific Discovery's Retained Earnings of $-49.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Lucy Scientific Discovery and its competitors. Lucy Scientific Discovery's current Retained Earnings is $-49.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current Retained Earnings of $-49.03 Mil. The current Retained Earnings is $-49.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current Retained Earnings is $-49.03 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.